Laitinen M, Mäkinen K, Manninen H, Matsi P, Kossila M, Agrawal R S, Pakkanen T, Luoma J S, Viita H, Hartikainen J, Alhava E, Laakso M, Ylä-Herttuala S
A.I. Virtanen Institute, Department of Medicine, University of Kuopio, Finland.
Hum Gene Ther. 1998 Jul 1;9(10):1481-6. doi: 10.1089/hum.1998.9.10-1481.
Arterial gene transfer offers a promising new approach for the treatment of vascular disorders. However, no data are available about the gene transfer efficiency in human arteries in vivo. The aim of this study was to evaluate the safety and feasibility of catheter-mediated adenoviral gene transfer in human peripheral arteries. Ten patients (8 females, 2 males, mean age 80 +/- 8 years) suffering from chronic critical leg ischemia with a prior decision for amputation were recruited in the study. Gene transfer was performed in eight patients in conjunction with a conventional percutaneous transluminal angioplasty, using a perfusion coil balloon catheter. Two patients served as controls. Increasing concentrations of replication-deficient adenoviruses (titers from 1 x 10(8) to 4 x 10(10) PFU) containing a nuclear-targeted beta-galactosidase marker gene were administered into the arteries over 10 min via the catheter. Amputations were performed 20 to 51 hr after the procedures and gene transfer efficiency was evaluated in the transduced arteries using X-Gal staining for beta-galactosidase activity. Beta-galactosidase gene transfer was well tolerated and no adverse tissue responses or systemic complications were observed in any of the patients. Gene transfer was successful in six of the eight patients. Gene transfer efficiency varied between 0.04 and 5.0% of all arterial cells. Transgene expression was detected in smooth muscle cells, endothelial cells, and macrophages and in tunica adventitia. However, transgene activity was not evenly distributed in the arterial wall and no transgene activity was found beneath advanced atherosclerotic lesions. The safety and feasibility of in vivo gene transfer by adenoviral vectors to human peripheral arteries were established. Although improvements are still required in gene transfer efficiency, these findings suggest that adenoviruses can be used to deliver therapeutically active genes into human arteries.
动脉基因转移为治疗血管疾病提供了一种很有前景的新方法。然而,目前尚无关于体内人类动脉基因转移效率的数据。本研究的目的是评估导管介导的腺病毒基因转移在人类外周动脉中的安全性和可行性。本研究招募了10例(8例女性,2例男性,平均年龄80±8岁)患有慢性严重下肢缺血且先前已决定截肢的患者。8例患者在进行传统经皮腔内血管成形术的同时,使用灌注线圈球囊导管进行基因转移。2例患者作为对照。通过导管在10分钟内将含有核靶向β-半乳糖苷酶标记基因的复制缺陷型腺病毒(滴度从1×10⁸到4×10¹⁰ PFU)以递增浓度注入动脉。术后20至51小时进行截肢,并使用X-Gal染色检测β-半乳糖苷酶活性,评估转导动脉中的基因转移效率。β-半乳糖苷酶基因转移耐受性良好,所有患者均未观察到不良组织反应或全身并发症。8例患者中有6例基因转移成功。基因转移效率在所有动脉细胞的0.04%至5.0%之间。在平滑肌细胞、内皮细胞、巨噬细胞和外膜中检测到转基因表达。然而,转基因活性在动脉壁中分布不均,在晚期动脉粥样硬化病变下方未发现转基因活性。确定了腺病毒载体向人类外周动脉进行体内基因转移的安全性和可行性。尽管基因转移效率仍需提高,但这些发现表明腺病毒可用于将治疗活性基因递送至人类动脉。